CompletedNot Applicable

Clinical and Molecular Effects of N-Acetylcysteine Treatment in COVID-19-Related Acute Respiratory Distress Syndrome

Turkey (Türkiye)59 participantsStarted 2020-11-01

Plain-language summary

Prospective, randomized, double-blind, placebo-controlled clinical trial evaluating the clinical and molecular effects of intravenous N-acetylcysteine (NAC) in patients with COVID-19-associated acute respiratory distress syndrome (ARDS) treated in the intensive care unit. The study assessed inflammatory and thromboinflammatory biomarkers, hypoxia-related gene expression (HIF-1α, ACE2, CD147), and clinical outcomes including mortality and length of ICU stay.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria:Age ≥18 years PCR-confirmed SARS-CoV-2 infection Diagnosis of acute respiratory distress syndrome (ARDS) according to the Berlin criteria Admission to the intensive care unit Written informed consent obtained from the patient or legal representative - Exclusion Criteria:Expected mortality within 48 hours of ICU admission Prior chronic oxygen therapy Previous COVID-19 treatment initiated at another center Pregnancy or breastfeeding Use of antioxidant or anti-inflammatory drugs within 30 days prior to enrollment Known hypersensitivity to N-acetylcysteine Use of medications affecting glutathione metabolism \-

What they're measuring

Change in inflammatory and thromboinflammatory biomarkers

Timeframe: Baseline (ICU admission) to Day 4

Trial details

NCT IDNCT07374991

SponsorUniversity of Gaziantep

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-06-10

View on ClinicalTrials.gov More COVID-19-Associated Acute Respiratory Distress Syndrome (ARDS) trials